SCHEMBL6893387

SCHEMBL6893387

Nc1cc(N2CCC(CC(=O)O)CC2)nc2c(-c3cccnc3)cnn12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 4/20 0.49
FFAR4 Q5NUL3 6/20 0.42
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
KDM4E B2RXH2 2/20 0.41
NPC1 O15118 2/20 0.41
ALDH1A1 P00352 2/20 0.41
TP53 P04637 2/20 0.41
MAPT P10636 2/20 0.41
HPGD P15428 2/20 0.41
MAPK1 P28482 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
HSD17B10 Q99714 2/20 0.41
MEN1 O00255 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
GFER P55789 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6891865 0.81 CHEK1 (0.51) CHEK1FFAR4CCNA2CDK2CCNA1
SCHEMBL6894483 0.79 EGFR (0.40) CHEK1FFAR4KDM4ENPC1ALDH1A1
SCHEMBL6894432 0.79 CHEK1 (0.46) CHEK1FFAR4CCNA2CDK2CCNA1
SCHEMBL6891509 0.71 NEK2 (0.42) CHEK1KDM4ENPC1ALDH1A1TP53
SCHEMBL6894442 0.69 MTOR (0.39) KDM4ENPC1ALDH1A1TP53MAPT
SCHEMBL7878563 0.69 PDE4B (0.40) FFAR4KDM4ENPC1ALDH1A1TP53
SCHEMBL6894431 0.69 CHEK1 (0.44) CHEK1CCNA2CDK2CCNA1
SCHEMBL17826798 0.69 CHEK1 (0.60) CHEK1CYP3A4CYP2C9CYP2C19KDM4E
SCHEMBL6893511 0.69 EGFR (0.38) CHEK1CYP3A4CYP2C9CYP2C19KDM4E
SCHEMBL6895987 0.68 CHEK1 (0.46) CHEK1CCNA2CDK2CCNA1PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. 2011-03-03 US disclosed
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS BACE1, BACE2, PSEN1 CHEK1 2755/4885FFAR4 3693/4885CYP3A4 2184/4885
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MTOR, RICTOR, RPTOR CHEK1 461/4885FFAR4 4116/4885CYP3A4 3581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.